Süt Hasan, Aynaoğlu Yıldız Gülşah, Şeker Erdal, Ümit Coşkun, Koçar Mustafa, Koç Acar
Department of Obstetrics and Gynecology, Ankara University Faculty of Medicine, Ankara, Turkey.
J Turk Ger Gynecol Assoc. 2023 Jun 7;24(2):120-124. doi: 10.4274/jtgga.galenos.2023.2022-9-10.
To investigate maternal adverse effects and perinatal and neonatal outcomes of women receiving coronavirus disease-2019 (COVID-19) vaccination during pregnancy.
Seven hundred and sixty pregnant women who were followed up in obstetrics outpatients were included in this prospective cohort study. COVID-19 vaccination and infection histories of the patients were recorded. Demographic data, including age, parity, and presence of systemic disease and adverse events following COVID-19 vaccination were recorded. Vaccinated pregnant women were compared with unvaccinated women in terms of adverse perinatal and neonatal outcomes.
Among the 760 pregnant women who met study criteria, the data of 425 pregnant women were analyzed. Among these, 55 (13%) were unvaccinated, 134 (31%) were vaccinated before pregnancy, and 236 (56%) pregnant women were vaccinated during pregnancy. Of those who were vaccinated, 307 patients (83%) received BioNTech, 52 patients (14%) received CoronaVac, and 11 patients (3%) received both CoronaVac and BioNTech. The local and systemic adverse effect profiles of patients who received COVID-19 vaccination either before or during pregnancy were similar (p=0.159), and the most common adverse effect was injection site pain. COVID-19 vaccination during pregnancy did not increase the ratio of abortion (<14 wk), stillbirth (>24 wk), preeclampsia, gestational diabetes mellitus, fetal growth restriction, second-trimester soft marker incidence, time of delivery, birth weight, preterm birth (<37 wk) or admission to the neonatal intensive care unit compared to the women who were not vaccinated during pregnacy.
COVID-19 vaccination during pregnancy did not increase maternal local and systemic adverse effects or poor perinatal and neonatal outcomes. Therefore, regarding the increased risk of morbidity and mortality related to COVID-19 in pregnant women, the authors propose that COVID-19 vaccination should be offered to all pregnant women.
探讨孕期接种2019冠状病毒病（COVID-19）疫苗的孕妇的母体不良反应以及围产期和新生儿结局。
本前瞻性队列研究纳入了760名在产科门诊接受随访的孕妇。记录患者的COVID-19疫苗接种和感染史。记录人口统计学数据，包括年龄、产次、全身性疾病的存在情况以及COVID-19疫苗接种后的不良事件。将接种疫苗的孕妇与未接种疫苗的孕妇在围产期和新生儿不良结局方面进行比较。
在符合研究标准的760名孕妇中，分析了425名孕妇的数据。其中，55名（13%）未接种疫苗，134名（31%）在孕前接种了疫苗，236名（56%）孕妇在孕期接种了疫苗。在接种疫苗的孕妇中，307例患者（83%）接种了辉瑞-BioNTech疫苗，52例患者（14%）接种了科兴新冠疫苗，11例患者（3%）同时接种了科兴新冠疫苗和辉瑞-BioNTech疫苗。在孕前或孕期接种COVID-19疫苗的患者的局部和全身不良反应情况相似（p=0.159），最常见的不良反应是注射部位疼痛。与孕期未接种疫苗的女性相比，孕期接种COVID-19疫苗并未增加流产（<14周）、死产（>24周）、子痫前期、妊娠期糖尿病、胎儿生长受限、孕中期软指标发生率、分娩时间、出生体重、早产（<37周）或入住新生儿重症监护病房的比例。
孕期接种COVID-19疫苗并未增加母体局部和全身不良反应或不良围产期和新生儿结局。因此，鉴于孕妇中与COVID-19相关的发病和死亡风险增加，作者建议应为所有孕妇提供COVID-19疫苗接种。
